LENZ Therapeutics, Inc. cash flow to debt ratio of -8.49K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

LENZ Therapeutics, Inc.'s free cash flow has decreased 16.94% from $-59.86M last year to $-70.00M, signaling decreasing performance

LENZ Therapeutics, Inc.'s debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability.

LENZ Therapeutics, Inc.'s debt has decreased relative to shareholder equity from 0.01 last year to 0.00 today, signaling strengthened financials

LENZ Therapeutics, Inc. has a net cash position, so leverage is healthy.

LENZ Therapeutics, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

LENZ Therapeutics, Inc. has insufficient data to evaluate this check.

LENZ Therapeutics, Inc.'s short-term assets of $301.41M exceed its short-term liabilities of $21.19M

LENZ Therapeutics, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

LENZ Therapeutics, Inc.'s return on equity of -46.82%, is lower than 15.00%, indicating bad performance

LENZ Therapeutics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

LENZ Therapeutics, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

LENZ Therapeutics, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

LENZ Therapeutics, Inc. has negative free cash flow, indicating cash burn

LENZ Therapeutics, Inc.'s yearly earnings has decreased 65.02% since last year from $-49.77M to $-82.13M, signaling decreasing performance

LENZ Therapeutics, Inc.'s yearly revenue has increased % since last year from $0.00 to $19.09M, signaling increasing performance

ROIC -47.88% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

LENZ Therapeutics, Inc.'s 3-year revenue CAGR of 8.37% is positive, indicating growing revenue over the past 3 years

LENZ Therapeutics, Inc. had revenue growth in 4 out of 5 years, indicating consistent revenue performance

LENZ Therapeutics, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

LENZ Therapeutics, Inc. has insufficient data to evaluate this check.

LENZ Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

LENZ Therapeutics, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

LENZ Therapeutics, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

LENZ Therapeutics, Inc. has insufficient data to evaluate this check.

LENZ Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

LENZ Therapeutics, Inc. has a price-to-book ratio of 0.68x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

LENZ Therapeutics, Inc. has a price-to-sales ratio of 8.01x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue